Just a few months after she was diagnosed with acute lymphoblastic leukemia (ALL) Laura Bray’s daughter Abby, then nine, encountered her first drug shortage.
Abby was among the 20% of ALL patients who develop allergies to E-coli-based enzymes used in the normally curative standard ALL treatment protocol to kill leukemic cells and must switch...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?